CPRX has been the topic of a number of other research reports. ValuEngine cut shares of Catalyst Pharmaceuticals from a strong-buy rating to a buy rating in a report on Wednesday, May 8th. Cantor Fitzgerald restated a buy rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, May 7th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $5.75 price objective on the stock in a research report on Wednesday. Finally, HC Wainwright set a $9.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, May 14th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $7.65.
Shares of NASDAQ:CPRX traded down $0.02 during trading on Friday, reaching $5.06. 1,026,108 shares of the stock traded hands, compared to its average volume of 1,094,889. The firm’s 50-day moving average price is $4.12. Catalyst Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.08. The company has a market capitalization of $522.50 million, a PE ratio of -15.33 and a beta of 2.59.
In related news, CEO Patrick J. Mcenany acquired 25,000 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were bought at an average price of $3.23 per share, for a total transaction of $80,750.00. Following the completion of the transaction, the chief executive officer now directly owns 4,762,693 shares in the company, valued at $15,383,498.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.70% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of CPRX. Gables Capital Management Inc. raised its position in Catalyst Pharmaceuticals by 1.3% in the second quarter. Gables Capital Management Inc. now owns 486,064 shares of the biopharmaceutical company’s stock worth $1,869,000 after acquiring an additional 6,300 shares during the period. Virtu Financial LLC raised its position in Catalyst Pharmaceuticals by 7.7% in the first quarter. Virtu Financial LLC now owns 112,568 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 8,062 shares during the period. Alps Advisors Inc. raised its position in Catalyst Pharmaceuticals by 4.5% in the first quarter. Alps Advisors Inc. now owns 248,154 shares of the biopharmaceutical company’s stock worth $1,266,000 after acquiring an additional 10,715 shares during the period. Lido Advisors LLC raised its position in Catalyst Pharmaceuticals by 11.8% in the first quarter. Lido Advisors LLC now owns 126,403 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 13,380 shares during the period. Finally, Amalgamated Bank bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth approximately $28,000. Institutional investors own 59.74% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Further Reading: What is a CD ladder?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.